The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas
Abstract
Purpose: Our previous clinical experience with vaccinia and replication-defective avipox recombinant carcinoembryonic antigen (CEA) vaccines has demonstrated safety and clinical activity with a correlation between CEA-specific immune response and survival. Preclinical evidence demonstrated that the addition of the transgenes for three T-cell costimulatory molecules (B7-1, ICAM-1, LFA-3, designated TRICOM) results in a significant improvement in antigen-specific T-cell responses and antitumor activity. We describe here the first trial in humans of the CEA-TRICOM vaccines (also including an enhancer agonist epitope within the CEA gene). Patients and Methods: Fifty-eight patients with advanced CEA-expressing cancers were accrued to eight cohorts that involved vaccinations with the following: replication-defective fowlpox recombinant (rF)-CEA(6D)-TRICOM; primary vaccination with recombinant vaccinia (rV)-CEA(6D)-TRICOM plus rF-CEA(6D)-TRICOM booster vaccinations; and rV-CEA(6D)-TRICOM and then rF-CEA(6D)-TRICOM, plus granulocyte-macrophage colony-stimulating factor (GM-CSF) with vaccines, or with divided doses of vaccine with GM-CSF. Vaccines were administered every 28 days for six doses and then once every 3 months. Reverting to treatments every 28 days was allowed if patients progressed on the 3-month schedule. Results: In this phase I study, no significant toxicity was observed. Twenty-three patients (40%) had stable disease for at least 4 months, with 14 of these patients having prolonged stable disease (> 6 months). Eleven patients had decreasing or stable serum CEA, and one patient had a pathologic complete response. Enhanced CEA-specific T-cell responses were observed in the majority of patients tested. Conclusion: We demonstrated that the CEA-TRICOM vaccines are safe and can generate significant CEA-specific immune responses, and they seem to have clinical benefit in some patients with advanced cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives
Thompson, J. A., Grunert, F., & Zimmermann, W. (1991) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.1860050510 · Cited by 608
Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy
Fong, L., Hou, Y., Rivas, A., Benike, C., Yuen, A., Fisher, G. A., Davis, M. M., & Engleman, E. G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.141226398 · Cited by 541
Tsang, K. Y., Zaremba, S., Nieroda, C. A., Zhu, M. Z., Hamilton, J. M., & Schlom, J. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.13.982 · Cited by 498
Self-citationMarshall, J. L., Hoyer, R. J., Toomey, M. A., Faraguna, K., Chang, P., Richmond, E., Pedicano, J. E., Gehan, E., Peck, R. A., Arlen, P., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.23.3964 · Cited by 357
Self-citationDisis, M., Bernhard, H., Shiota, F., Hand, S., Gralow, Jr., Huseby, E., Gillis, S., & Cheever, M. (1996) · Blood · doi:10.1182/blood.v88.1.202.202 · Cited by 329
J�ger, E., Ringhoffer, M., Dienes, H. P., Arand, M., Karbach, J., J�ger, D., Ilsemann, C., Hagedorn, M., Oesch, F., & Knuth, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960703)67:1<54::aid-ijc11>3.0.co;2-c · Cited by 299
A triad of costimulatory molecules synergize to amplify T-cell activation.
Hodge, J. W., Sabzevari, H., Yafal, A. G., Gritz, L. R., Lorenz, M. G., & Schlom, J. (1999) · PubMed · Cited by 297
Self-citationEder, J. P., Kantoff, P. W., Röper, K., Xu, G., Bubley, G. J., Boyden, J., Gritz, L. R., Mazzara, G. P., Oh, W. K., Arlen, P. M., et al. (2000) · PubMed · Cited by 294
Self-citationNemunaitis, J., Sterman, D., Jablons, D., Smith, J. W., Fox, B., Maples, P., Hamilton, S., Borellini, F., Lin, A., Morali, S., et al. (2004) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djh028 · Cited by 244
Zaremba, S., Barzaga, E., Zhu, M., Soares, N., Tsang, K. Y., & Schlom, J. (1997) · PubMed · Cited by 204
Self-citation
Cited by
Kantoff, P. W., Schuetz, T. J., Blumenstein, B. A., Glode, L. M., Bilhartz, D. L., Wyand, M., Manson, K., Panicali, D. L., Laus, R., Schlom, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.0597 · Cited by 982
Self-citationCD8 + T‐cell memory in tumor immunology and immunotherapy
Klebanoff, C. A., Gattinoni, L., & Restifo, N. P. (2006) · Immunological Reviews · doi:10.1111/j.0105-2896.2006.00391.x · Cited by 511
Exploiting the curative potential of adoptive T‐cell therapy for cancer
Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466
Laheru, D., Lutz, E., Burke, J., Biedrzycki, B., Solt, S., Onners, B., Tartakovsky, I., Nemunaitis, J., Le, D., Sugar, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0371 · Cited by 346
Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients
Parmiani, G., Castelli, C., Pilla, L., Santinami, M., Colombo, M. P., & Rivoltini, L. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl158 · Cited by 300
Metadata
- Authors
- Marshall, J. L., Gulley, J. L., Arlen, P. M., Beetham, P. K., Tsang, K.-Y., Slack, R., Hodge, J. W., Doren, S., Grosenbach, D. W., Hwang, J., Fox, E., Odogwu, L., Park, S., Panicali, D., & Schlom, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2005-02-01
- Volume
- 23
- Issue
- 4
- Pages
- 720-731
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2146934263
- Cited by
- 297
- References
- 27
- FWCI
- 10.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas. https://app.cochat.ai/papers/10.1200/jco.2005.10.206
- The paper
- Marshall, J. L., Gulley, J. L., Arlen, P. M., Beetham, P. K., Tsang, K.-Y., Slack, R., Hodge, J. W., Doren, S., Grosenbach, D. W., Hwang, J., Fox, E., Odogwu, L., Park, S., Panicali, D., & Schlom, J. (2005). Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2005.10.206
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.